Maxim Group Releases a Buy Rating on BeiGene Ltd

By Carrie Williams

In a report released today, Gabrielle Zhou from Maxim Group reiterated a Buy rating on BeiGene Ltd (NASDAQ: BGNE), with a price target of $52. The company’s shares opened today at $36.88.

Zhou observed:

“BeiGene announced the initiation (first patient dosed) of a pivotal study of BGB-A317 (anti-PD-1) in China in patients with relapsed/refractory classical Hodgkin lymphoma (cHL).”

According to TipRanks.com, Zhou is a 1-star analyst with an average return of -2.4% and a 31.6% success rate. Zhou covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sciclone Pharmaceuticals, and Mateon Therapeutics Inc.

BeiGene Ltd has an analyst consensus of Moderate Buy.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeiGene Ltd. operates as a holding company, which engages in the research and development of biopharmaceutical products. It develops immuno-oncology drugs for cancer treatment. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.